{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:40Z","timestamp":1792086520438,"version":"4.4.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/V004697\/1"],"award-info":[{"award-number":["BB\/V004697\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/V004697\/1"],"award-info":[{"award-number":["BB\/V004697\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_0034\/3"],"award-info":[{"award-number":["MC_UU_0034\/3"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00034\/6"],"award-info":[{"award-number":["MC_UU_00034\/6"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Infections by endemic viruses, and the vaccines used to control them, often provide cross-protection against related viruses, potentially altering the transmission dynamics and likelihood of emergence of new zoonotic viruses with pandemic potential. Here, we investigate how population immunity after the COVID-19 pandemic has impacted the likelihood of emergence of a novel sarbecovirus, termed SARS-CoV-X. To this end, we combined empirical cross-neutralisation data with mathematical modelling to identify key immunological and epidemiological factors shaping sarbecovirus emergence. We show that sera from individuals with different COVID-19 immunological histories contained cross-neutralising antibodies against the spike (S) protein of multiple zoonotic sarbecoviruses. Simulations parameterised by these data predict that the likelihood of emergence of a novel sarbecovirus has been reduced significantly by population cross-immunity, with outcomes determined by the extent of cross-protection and R0 of the novel virus. Preventative vaccination against SARS-CoV-X using available COVID-19 vaccines can help resist emergence even in the presence of co-circulating SARS-CoV-2. However, a theoretical vaccine with high specificity to SARS-CoV-2 can increase emergence probability by suppressing SARS-CoV-2 prevalence and, by extension, levels of natural cross-protection. Overall, SARS-CoV-2 circulation and vaccination have generated widespread immunity against related sarbecoviruses, creating an immunological barrier to novel sarbecovirus emergence in humans.<\/jats:p>","DOI":"10.1038\/s41467-026-69988-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:01:30Z","timestamp":1774346490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-2888","authenticated-orcid":false,"given":"Ryan M.","family":"Imrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Bissett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitha","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Manali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien A. R.","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mojsiejczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-6015","authenticated-orcid":false,"given":"Nicola","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4080-7274","authenticated-orcid":false,"given":"Andrew","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3867-1953","authenticated-orcid":false,"given":"Marc","family":"Baguelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-6505","authenticated-orcid":false,"given":"Mafalda","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-3266","authenticated-orcid":false,"given":"Brian J.","family":"Willett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-394X","authenticated-orcid":false,"given":"Pablo R.","family":"Murcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"69988_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cell.2015.10.019","volume":"163","author":"SF Kluge","year":"2015","unstructured":"Kluge, S. F., Sauter, D. & Kirchhoff, F. SnapShot: antiviral restriction factors. Cell 163, 774\u2013774.e1 (2015).","journal-title":"Cell"},{"key":"69988_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12985-024-02287-0","volume":"21","author":"A Letafati","year":"2024","unstructured":"Letafati, A. et al. Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications. Virol. J. 21, 18 (2024).","journal-title":"Virol. J."},{"key":"69988_CR3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"C-H Koh","year":"2023","unstructured":"Koh, C.-H., Lee, S., Kwak, M., Kim, B.-S. & Chung, Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp. Mol. Med. 55, 2287\u20132299 (2023).","journal-title":"Exp. Mol. Med."},{"key":"69988_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nri888","volume":"2","author":"MG Katze","year":"2002","unstructured":"Katze, M. G., He, Y. & Gale, M. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2, 675\u2013687 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"69988_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","volume":"23","author":"DR Burton","year":"2023","unstructured":"Burton, D. R. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat. Rev. Immunol. 23, 720\u2013734 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"69988_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nature05775","volume":"447","author":"ND Wolfe","year":"2007","unstructured":"Wolfe, N. D., Dunavan, C. P. & Diamond, J. Origins of major human infectious diseases. Nature 447, 279\u2013283 (2007).","journal-title":"Nature"},{"key":"69988_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00705-020-04628-0","volume":"165","author":"VGda Costa","year":"2020","unstructured":"Costa, V. G. da, Moreli, M. L. & Saivish, M. V. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. Arch. Virol. 165, 1517\u20131526 (2020).","journal-title":"Arch. Virol."},{"key":"69988_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1203\/01.PDR.0000129184.87042.FC","volume":"56","author":"JD Cherry","year":"2004","unstructured":"Cherry, J. D. & Krogstad, P. SARS: the first pandemic of the 21st century. Pediatr. Res. 56, 1\u20135 (2004).","journal-title":"Pediatr. Res."},{"key":"69988_CR9","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3201\/eid1112.041293","volume":"11","author":"M Wang","year":"2005","unstructured":"Wang, M. et al. SARS-CoV infection in a restaurant from Palm Civet. Emerg. Infect. Dis. 11, 1860\u20131865 (2005).","journal-title":"Emerg. Infect. Dis."},{"key":"69988_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"Wit","year":"2016","unstructured":"Wit et al. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523\u2013534 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"69988_CR11","unstructured":"European Centre for Disease Prevention and Control, MERS-CoV worldwide overview. (accessed 04\/02\/2026) https:\/\/www.ecdc.europa.eu\/en\/middle-east-respiratory-syndrome-coronavirus-mers-cov-situation-update"},{"key":"69988_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrp.2015.08.006","volume":"6","author":"Korea Centers for Disease Control and Prevention","year":"2015","unstructured":"Korea Centers for Disease Control and Prevention Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015. Osong Public Heal. Res. Perspect. 6, 269\u2013278 (2015).","journal-title":"Osong Public Heal. Res. Perspect."},{"key":"69988_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","volume":"397","author":"OJ Wouters","year":"2021","unstructured":"Wouters, O. J. et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397, 1023\u20131034 (2021).","journal-title":"Lancet"},{"key":"69988_CR14","unstructured":"Total COVID-19 vaccine doses administered. (accessed 04\/02\/2026) https:\/\/ourworldindata.org\/grapher\/cumulative-covid-vaccinations?tab=table"},{"key":"69988_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/v14030640","volume":"14","author":"N Magazine","year":"2022","unstructured":"Magazine, N. et al. Mutations and Evolution of the SARS-CoV-2 Spike Protein. Viruses 14, 640 (2022).","journal-title":"Viruses"},{"key":"69988_CR16","doi-asserted-by":"publisher","first-page":"2101196","DOI":"10.2807\/1560-7917.ES.2022.27.4.2101196","volume":"27","author":"D Eggink","year":"2022","unstructured":"Eggink, D. et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Eurosurveillance 27, 2101196 (2022).","journal-title":"Eurosurveillance"},{"key":"69988_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"69988_CR18","unstructured":"PHS. Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 August 2022. (accessed 04\/02\/2026) https:\/\/publichealthscotland.scot\/publications\/enhanced-surveillance-of-covid-19-in-scotland\/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-august-2022\/"},{"key":"69988_CR19","doi-asserted-by":"publisher","first-page":"13396","DOI":"10.1073\/pnas.1516698112","volume":"112","author":"S Bhattacharyya","year":"2015","unstructured":"Bhattacharyya, S., Gesteland, P. H., Korgenski, K., Bj\u00f8rnstad, O. N. & Adler, F. R. Cross-immunity between strains explains the dynamical pattern of paramyxoviruses. Proc. Natl. Acad. Sci. 112, 13396\u201313400 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"69988_CR20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.aat6777","volume":"361","author":"M Pons-Salort","year":"2018","unstructured":"Pons-Salort, M. & Grassly, N. C. Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science 361, 800\u2013803 (2018).","journal-title":"Science"},{"key":"69988_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","volume":"29","author":"JJ Lau","year":"2023","unstructured":"Lau, J. J. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29, 348\u2013357 (2023).","journal-title":"Nat. Med."},{"key":"69988_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","volume":"29","author":"C Kurhade","year":"2023","unstructured":"Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29, 344\u2013347 (2023).","journal-title":"Nat. Med."},{"key":"69988_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s44149-021-00005-9","volume":"1","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z., Qiu, Y. & Ge, X. The taxonomy, host range and pathogenicity of coronaviruses and other viruses in the Nidovirales order. Anim. Dis. 1, 5 (2021).","journal-title":"Anim. Dis."},{"key":"69988_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41579-021-00652-2","volume":"20","author":"M Ruiz-Aravena","year":"2022","unstructured":"Ruiz-Aravena, M. et al. Ecology, evolution and spillover of coronaviruses from bats. Nat. Rev. Microbiol. 20, 299\u2013314 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"69988_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41586-022-04532-4","volume":"604","author":"S Temmam","year":"2022","unstructured":"Temmam, S. et al. Bat coronaviruses related to SARS-CoV-2 and infectious for human cells. Nature 604, 330\u2013336 (2022).","journal-title":"Nature"},{"key":"69988_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","volume":"583","author":"TT-Y Lam","year":"2020","unstructured":"Lam, T. T.-Y. et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 583, 282\u2013285 (2020).","journal-title":"Nature"},{"key":"69988_CR27","doi-asserted-by":"publisher","first-page":"20200358","DOI":"10.1098\/rstb.2020.0358","volume":"376","author":"CJ Carlson","year":"2021","unstructured":"Carlson, C. J. et al. The future of zoonotic risk prediction. Philos. Trans. R. Soc. B 376, 20200358 (2021).","journal-title":"Philos. Trans. R. Soc. B"},{"key":"69988_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/d41586-018-05373-w","volume":"558","author":"EC Holmes","year":"2018","unstructured":"Holmes, E. C., Rambaut, A. & Andersen, K. G. Pandemics: spend on surveillance, not prediction. Nature 558, 180\u2013182 (2018).","journal-title":"Nature"},{"key":"69988_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48180-w","volume":"15","author":"MT Berry","year":"2024","unstructured":"Berry, M. T. et al. Predicting vaccine effectiveness for mpox. Nat. Commun. 15, 3856 (2024).","journal-title":"Nat. Commun."},{"key":"69988_CR30","unstructured":"Coronavirus (COVID-19) Infection Survey, UK - Office for National Statistics. (accessed 04\/02\/2026) https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/coronaviruscovid19infectionsurveypilot\/24march2023"},{"key":"69988_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1126\/science.aag1322","volume":"354","author":"KM Gostic","year":"2016","unstructured":"Gostic, K. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354, 722\u2013726 (2016).","journal-title":"Science"},{"key":"69988_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/v12091011","volume":"12","author":"I Hyseni","year":"2020","unstructured":"Hyseni, I. et al. Characterisation of SARS-CoV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays. Viruses 12, 1011 (2020).","journal-title":"Viruses"},{"key":"69988_CR33","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","volume":"387","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. A Covid-19 milestone attained\u2014a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203\u20132206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","volume":"162","author":"RT Chen","year":"1990","unstructured":"Chen, R. T. et al. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162, 1036\u20131042 (1990).","journal-title":"J. Infect. Dis."},{"key":"69988_CR35","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1128\/JVI.00115-06","volume":"80","author":"V Panchanathan","year":"2006","unstructured":"Panchanathan, V., Chaudhri, G. & Karupiah, G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80, 6333\u20136338 (2006).","journal-title":"J. Virol."},{"key":"69988_CR36","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1038\/s41564-022-01246-1","volume":"7","author":"CW Tan","year":"2022","unstructured":"Tan, C. W. et al. SARS-CoV-2 Omicron variant emerged under immune selection. Nat. Microbiol. 7, 1756\u20131761 (2022).","journal-title":"Nat. Microbiol."},{"key":"69988_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj0070","volume":"382","author":"SH Wilks","year":"2023","unstructured":"Wilks, S. H. et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382, eadj0070 (2023).","journal-title":"Science"},{"key":"69988_CR38","doi-asserted-by":"crossref","unstructured":"Chemaitelly, H. et al. Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron. Nature 1\u20138, (2025).","DOI":"10.1038\/s41586-024-08511-9"},{"key":"69988_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2213907","volume":"388","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Antibody response to Omicron BA.4\u2013BA.5 bivalent booster. N. Engl. J. Med. 388, 567\u2013569 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1056\/NEJMc2213948","volume":"388","author":"AY Collier","year":"2023","unstructured":"Collier, A. Y. et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N. Engl. J. Med. 388, 565\u2013567 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104062","volume":"80","author":"S Col\u00e9on","year":"2022","unstructured":"Col\u00e9on, S. et al. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. eBioMedicine 80, 104062 (2022).","journal-title":"eBioMedicine"},{"key":"69988_CR42","doi-asserted-by":"crossref","unstructured":"Bergen, J. van. et al. Multi-antigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses. JCI Insight 8, e172488 (2023).","DOI":"10.1172\/jci.insight.172488"},{"key":"69988_CR43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"69988_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","volume":"21","author":"S Cankat","year":"2024","unstructured":"Cankat, S., Demael, M. U. & Swadling, L. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cell. Mol. Immunol. 21, 103\u2013118 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"69988_CR45","first-page":"1","volume":"71","author":"R Nachbagauer","year":"2019","unstructured":"Nachbagauer, R. & Palese, P. Is a universal influenza virus vaccine possible? Annu. Rev. Med. 71, 1\u201313 (2019).","journal-title":"Annu. Rev. Med."},{"key":"69988_CR46","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","volume":"75","author":"PWHI Parren","year":"2001","unstructured":"Parren, P. W. H. I. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 Simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340\u20138347 (2001).","journal-title":"J. Virol."},{"key":"69988_CR47","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201993","volume":"218","author":"A Sch\u00e4fer","year":"2020","unstructured":"Sch\u00e4fer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 218, e20201993 (2020).","journal-title":"J. Exp. Med."},{"key":"69988_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156 (2024).","journal-title":"Nature"},{"key":"69988_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp9927","volume":"16","author":"R Kotaki","year":"2024","unstructured":"Kotaki, R. et al. Repeated Omicron exposures redirect SARS-CoV-2\u2013specific memory B cell evolution toward the latest variants. Sci. Transl. Med. 16, eadp9927 (2024).","journal-title":"Sci. Transl. Med."},{"key":"69988_CR51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"NL Bert","year":"2020","unstructured":"Bert, N. L. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457\u2013462 (2020).","journal-title":"Nature"},{"key":"69988_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10654-022-00905-1","volume":"37","author":"G Bucyibaruta","year":"2022","unstructured":"Bucyibaruta, G., Blangiardo, M. & Konstantinoudis, G. Community-level characteristics of COVID-19 vaccine hesitancy in England: a nationwide cross-sectional study. Eur. J. Epidemiol. 37, 1071\u20131081 (2022).","journal-title":"Eur. J. Epidemiol."},{"key":"69988_CR53","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S0140-6736(16)30164-7","volume":"388","author":"CJE Metcalf","year":"2016","unstructured":"Metcalf, C. J. E. et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet 388, 728\u2013730 (2016).","journal-title":"Lancet"},{"key":"69988_CR54","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","volume":"637","author":"TP Peacock","year":"2025","unstructured":"Peacock, T. P. et al. The global H5N1 influenza panzootic in mammals. Nature 637, 304\u2013313 (2025).","journal-title":"Nature"},{"key":"69988_CR55","unstructured":"CDC. H5 Bird Flu: Current Situation\u2013CDC. (accessed 04\/02\/2026) https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html"},{"key":"69988_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.01.042","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.01.042 (2025).","journal-title":"Cell"},{"key":"69988_CR57","unstructured":"WHO. Pathogens Prioritization: A scientific Framework for Epidemic and Pandemic Research Preparedness. (accessed 04\/02\/2026) https:\/\/www.who.int\/publications\/m\/item\/pathogens-prioritization-a-scientific-framework-for-epidemic-and-pandemic-research-preparedness"},{"key":"69988_CR58","unstructured":"UKHSA. Priority pathogen families research and development tool. (accessed 04\/02\/2026) https:\/\/www.gov.uk\/government\/publications\/priority-pathogen-families-research-and-development-tool"},{"key":"69988_CR59","unstructured":"International Pandemic Preparedness Secretariat. 100 Days Mission to Respond to Future Pandemic Threats: A report to the G7 by the pandemic preparedness partnership. (accessed 04\/02\/2026) https:\/\/assets.publishing.service.gov.uk\/media\/60c20a14e90e07438ee5748f\/100_Days_Mission_to_respond_to_future_pandemic_threats__3_.pdf"},{"key":"69988_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263\u2013267 (1996).","journal-title":"Science"},{"key":"69988_CR61","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873\u20139880 (1998).","journal-title":"J. Virol."},{"key":"69988_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/infdis\/jiac332","volume":"227","author":"M Manali","year":"2022","unstructured":"Manali, M. et al. SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. J. Infect. Dis. 227, 40\u201349 (2022).","journal-title":"J. Infect. Dis."},{"key":"69988_CR63","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/infdis\/jiaa788","volume":"223","author":"EC Hughes","year":"2020","unstructured":"Hughes, E. C. et al. Severe acute respiratory syndrome coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting. J. Infect. Dis. 223, 971\u2013980 (2020).","journal-title":"J. Infect. Dis."},{"key":"69988_CR64","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/nar\/gkh340","volume":"32","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792\u20131797 (2004).","journal-title":"Nucleic Acids Res."},{"key":"69988_CR65","doi-asserted-by":"publisher","first-page":"vey016","DOI":"10.1093\/ve\/vey016","volume":"4","author":"MA Suchard","year":"2018","unstructured":"Suchard, M. A. et al. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol. 4, vey016 (2018).","journal-title":"Virus Evol."},{"key":"69988_CR66","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1371\/journal.pbio.0040088","volume":"4","author":"AJ Drummond","year":"2006","unstructured":"Drummond, A. J., Ho, S. Y. W., Phillips, M. J. & Rambaut, A. Relaxed phylogenetics and dating with confidence. PLoS Biol. 4, e88 (2006).","journal-title":"PLoS Biol."},{"key":"69988_CR67","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jtbi.2008.04.005","volume":"253","author":"T Gernhard","year":"2008","unstructured":"Gernhard, T. The conditioned reconstructed process. J. Theor. Biol. 253, 769\u2013778 (2008).","journal-title":"J. Theor. Biol."},{"key":"69988_CR68","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/sysbio\/syy032","volume":"67","author":"A Rambaut","year":"2018","unstructured":"Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior summarization in Bayesian phylogenetics using tracer 1.7. Syst. Biol. 67, 901\u2013904 (2018).","journal-title":"Syst. Biol."},{"key":"69988_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/2041-210X.12628","volume":"8","author":"G Yu","year":"2017","unstructured":"Yu, G., Smith, D. K., Zhu, H., Guan, Y. & Lam, T. T. ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods Ecol. Evol. 8, 28\u201336 (2017).","journal-title":"Methods Ecol. Evol."},{"key":"69988_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050074","volume":"5","author":"J Mossong","year":"2008","unstructured":"Mossong, J. et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5, e74 (2008).","journal-title":"PLoS Med."},{"key":"69988_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003907","volume":"19","author":"A Gimma","year":"2022","unstructured":"Gimma, A. et al. Changes in social contacts in England during the COVID-19 pandemic between March 2020 and March 2021 as measured by the CoMix survey: A repeated cross-sectional study. PLoS Med. 19, e1003907 (2022).","journal-title":"PLoS Med"},{"key":"69988_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2024.100778","volume":"48","author":"CI Jarvis","year":"2024","unstructured":"Jarvis, C. I. et al. Social contact patterns following the COVID-19 pandemic: a snapshot of post-pandemic behaviour from the CoMix study. Epidemics 48, 100778 (2024).","journal-title":"Epidemics"},{"key":"69988_CR73","unstructured":"R-Core-Team. R: A Language and Environment for Statistical Computing. (2024)."},{"key":"69988_CR74","doi-asserted-by":"publisher","first-page":"758294","DOI":"10.3389\/fimmu.2021.758294","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang, J., Tong, Y., Li, D., Li, J. & Li, Y. The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front. Immunol. 12, 758294 (2021).","journal-title":"Front. Immunol."},{"key":"69988_CR75","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR76","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR77","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N. Engl. J. Med. 385, 2348\u20132360 (2021).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR78","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"69988_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28527-x","volume":"13","author":"H Ward","year":"2022","unstructured":"Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13, 907 (2022).","journal-title":"Nat. Commun."},{"key":"69988_CR80","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/S2666-5247(23)00005-8","volume":"4","author":"S Galmiche","year":"2023","unstructured":"Galmiche, S. et al. SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study. Lancet Microbe 4, e409\u2013e417 (2023).","journal-title":"Lancet Microbe"},{"key":"69988_CR81","doi-asserted-by":"publisher","first-page":"905020","DOI":"10.3389\/fpubh.2022.905020","volume":"10","author":"C Achangwa","year":"2022","unstructured":"Achangwa, C., Park, H. & Ryu, S. Incubation period of wild type of SARS-CoV-2 infections by age, gender, and epidemic periods. Front. Public Health 10, 905020 (2022).","journal-title":"Front. Public Health"},{"key":"69988_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/aje\/kwj034","volume":"163","author":"Q-C Cai","year":"2006","unstructured":"Cai, Q.-C. et al. Refined estimate of the incubation period of severe acute respiratory syndrome and related influencing factors. Am. J. Epidemiol. 163, 211\u2013216 (2006).","journal-title":"Am. J. Epidemiol."},{"key":"69988_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252217","volume":"16","author":"SP Phillips","year":"2021","unstructured":"Phillips, S. P. et al. Duration of SARS-CoV-2 shedding: a population-based, Canadian study. PLoS ONE 16, e0252217 (2021).","journal-title":"PLoS ONE"},{"key":"69988_CR84","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70458","volume":"10","author":"PZ Chen","year":"2021","unstructured":"Chen, P. Z. et al. SARS-CoV-2 shedding dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19. eLife 10, e70458 (2021).","journal-title":"eLife"},{"key":"69988_CR85","unstructured":"PHS. COVID-19 Vaccination in Scotland. (accessed 04\/02\/2026) https:\/\/www.opendata.nhs.scot\/dataset\/covid-19-vaccination-in-scotland\/resource\/9b99e278-b8d8-47df-8d7a-a8cf98519ac1"},{"key":"69988_CR86","unstructured":"PHS. Seasonal immunisations\u2013Public Health Scotland. (accessed 04\/02\/2026) https:\/\/publichealthscotland.scot\/population-health\/health-protection\/immunisation-vaccine-and-preventable-disease\/seasonal-immunisations\/"},{"key":"69988_CR87","unstructured":"King, A. A. & Ionides, E. L. Simulation of stochastic dynamic models. (accessed 04\/02\/2026) https:\/\/kingaa.github.io\/short-course\/stochsim\/stochsim.html"},{"key":"69988_CR88","unstructured":"FitzJohn, R. Odin: ODE Generation and Integration. (2024)."},{"key":"69988_CR89","unstructured":"FitzJohn, R., Hill, A. & Lees, J. Odin.dust: Compile Odin to Dust. (2024)."},{"key":"69988_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jinf.2020.03.022","volume":"81","author":"KJ Hill","year":"2020","unstructured":"Hill, K. J. et al. The index case of SARS-CoV-2 in Scotland. J. Infect. 81, 147\u2013178 (2020).","journal-title":"J. Infect."},{"key":"69988_CR91","doi-asserted-by":"publisher","first-page":"e01238","DOI":"10.1002\/ecs2.1238","volume":"7","author":"TAA Prowse","year":"2016","unstructured":"Prowse, T. A. A. et al. An efficient protocol for the global sensitivity analysis of stochastic ecological models. Ecosphere 7, e01238 (2016).","journal-title":"Ecosphere"},{"key":"69988_CR92","doi-asserted-by":"publisher","unstructured":"Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. arXiv (2016) https:\/\/doi.org\/10.48550\/arxiv.1603.02754","DOI":"10.48550\/arxiv.1603.02754"},{"key":"69988_CR93","unstructured":"Iooss B. et al. sensitivity: Global Sensitivity Analysis of Model Outputs and Importance Measures. R package version 1.30.1."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69988-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69988-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69988-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:01:41Z","timestamp":1774346501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69988-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69988"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69988-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2248"}}